secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vaxcyte, Inc. (PCVX)
CIK:        0001649094
Form:       8-K
Filed at:   2026-08-05T20:07:51+00:00
Accession:  0001649094-26-000041
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vaxcyte Q2 net loss $284M; VAX-31 OPUS-1 topline data expected Q4 2026
----------------------------------------------------------------------

- Net loss of $284.3M in Q2 2026 vs $166.6M in Q2 2025; R&D expenses rose to $267.9M.
- Cash, equivalents and investments $2.5B as of June 30, 2026, up from $2.44B at year-end 2025.
- VAX-31 adult Phase 3 OPUS-1 noninferiority trial fully enrolled; topline data due Q4 2026.
- VAX-31 infant Phase 2 dose-finding study data expected by end of H1 2027.
- Phase 1 study of VAX-A1 (Group A Strep) initiated; topline data expected H2 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1649094/000164909426000041/0001649094-26-000041-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1649094/000164909426000041/pcvx-20260805.htm
  HTML page:      https://secwatch.observer/filing/0001649094-26-000041

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer